Cancer Exosomes

8/4/2019 Cancer Exosomes

1/34

A Novel Therapeutic Strategyto AddressCancer

September 2011


2/34

Canceris the leading cause of deathworldwide and accounted for 7.6 million

deaths in 2008 alone


3/34

There were 12.7 million new cases ofCancer in 2008


4/34

Cancerdeaths in the United Statesare expected to exceed 570,000 in 2011


5/34


6/34

In 2011, new cases of Cancer areexpected to exceed 1,500,000 in the U.S.


7/34


8/34

Innovative strategies are needed

to address Cancer progressionmechanisms that are beyond thereach of current drug therapies


9/34

A therapeutic strategy that could inhibit the

proliferation of immunosuppressive exosomesreleased by solid tumors, lymphomas andleukemias would fill a significant unmetmedical need in cancer care


10/34

What are Exosomes?

Cancer cells, both in vivoand in vitro, have beendemonstrated to releasemembranous structures,defined as exosomes


11/34

Researchers have recently unveiled severalroles that exosomes play in acceleratingcancer progression


12/34

The resulting research publicationsare reporting that................


13/34

Exosomes cause apoptosis or programmedcell death of immune cells


14/34

Exosomes disrupt signaling ofanti-cancer T cells


15/34

Exosomes contribute to tumor angiogenesis


16/34

Exosomes enhance the spread of tumor metastasis


17/34

The quantity of exosomes in circulation is indirect correlation with cancer progression


18/34

What if exosomes could beeliminated from circulation?


19/34

The first therapeutic candidate to eliminatecancer exosomes from circulation

The Aethlon Hemopurifier


20/34

The Aethlon Hemopurifier

Provides a therapeutic filtration

mechanism to remove cancer

exosomes from the circulatory

system

Allows selective exosome capture

via unique high-mannose

signatures resident on exosomesurfaces


21/34

Providing access to the entire

circulatory system

Exosomes can be accessed

from entire circulatory system,

which can pass through the

Hemopurifier in as little as

15 minutes


22/34

Hemopurifier therapy has the advantage of being

delivered through the global infrastructure of dialysis

machines that are already located in hospitals in clinics


23/34

Our goal is to improve patient responsivenessto traditional chemotherapies and emergingclasses of immune based therapies


24/34

To improve patient responsiveness withoutadditional drug toxicity or interaction risks


25/34

In vitro binding of exosomes underlying thefollowing cancers has been demonstrated

Breast

Ovarian

Colorectal

Lymphoma

Melanoma


26/34

Human Hemopurifier treatmentexperience already exists


27/34

The Hemopurifier has previously demonstrated

the ability to reduce viral load in HIV andhepatitis C (HCV) infected individuals without theadministration of antiviral drugs


28/34

A clinical study to evaluate the ability of the

Hemopurifier to improve HCV drug therapybenefit is currently being conducted


29/34

The clinical application of theHemopurifier in Cancer?


30/34

We are currently col laborating withcandidate investigators to develop a clinicalprotocol to demonstrate the ability of ourHemopurifier to eliminate circulatingcancer exosomes


31/34

We invite you to follow our efforts

to improve cancer care

AethlonMedical.com


32/34

Our mission is to create innovative devices thataddress unmet medical needs in cancer, infectious

disease, and other life-threatening conditions

Thank You


33/34

Contact

Jim Joyce

Chairman, CEO

8910 University Center Lane

San Diego, California [email protected]


34/34

This presentation contains forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995, and Aethlon Medical intends that such forward-looking statements be

subject to the safe harbor created thereby. These statements are based on managements current

expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could

cause actual results to differ materially from those described. All statements, other than statements of

historical fact, are statements that could be deemed forward-looking statements, including the companys

ability to successfully obtain FDA and other regulatory approvals for the sale of its products, the

capability of the Hemopurifier to reduce viral loads and other disease conditions or to identify or treatdisease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the

impact that potential ability may have on disease conditions, and the companys ability to raise capital

when needed.

Some information in this presentation, or on which this presentation is based, has been obtained from

sources that Aethlon Medical, Inc., believes to be reliable and accurate. However, it has not been

independently verified and no representation or warranty, express or implied, is made as to the accuracy

or completeness of any information obtained from third parties.

Such risks and uncertainties, including those discussed above, are more fully described in the Securities

and Exchange Commission (SEC) reports filed by Aethlon Medical, Inc., including its most recent annual

report on Form 10-K. This presentation speaks only as of its date, and the company disclaims any duty

to update the information herein. Further information is available by contacting the company or at the

companys website at www.aethlonmedical.com.

Documents

Cancer Exosomes